GYRE WACC: 10.26% for Gyre Therapeutics, Inc. Common Stock
Current inputs imply a 10.26% cost of equity and a 5.00% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.
WACC Calculator
Values are automatically populated from real data. You can adjust them manually if needed.
Please enter a valid company ticker to calculate WACC
Gyre Therapeutics, Inc. Common Stock (GYRE) WACC in context
Gyre Therapeutics, Inc. Common Stock (GYRE) currently screens with an estimated WACC of 10.26%. That blends a 10.26% cost of equity, a 5.00% pre-tax cost of debt, and a 100.00% equity weight into the discount rate you would typically use in a DCF model.
falls into a common range for established public companies and is a practical DCF starting point.
A 10.26% discount rate falls into a common range for established public companies and is a practical DCF starting point.
This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 1.50 and equity accounts for 100.00% of capital.
Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.